Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Anima in the transaction. AbbVie (NYSE: ABBV) and Anima Biotech (Anima) have announced a collaboration to discover and develop mRNA biology modulators...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Alphatec in the transactions. Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focusing on surgical treatment for spinal disorders has...
You must be a Standard 1 Year member to access this content.
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Alpine, while Latham & Watkins represented to underwriters in the offering. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
You must be a Standard 1 Year member to access this content.
Cooley represented Mirum Pharmaceuticals, while Latham & Watkins represented the underwriters in the offering. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
You must be a Standard 1 Year member to access this content.
